This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $591.13 in the latest trading session, marking a -1.09% move from the prior day.
Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted
by Zacks Equity Research
FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Regeneron (REGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed the most recent trading day at $586.84, moving -0.14% from the previous trading session.
Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last?
by Zacks Equity Research
Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Regeneron (REGN) Stock Moves -0.79%: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $556.75 in the latest trading session, marking a -0.79% move from the prior day.
Regeneron (REGN) Stock Moves -0.64%: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $571.81 in the latest trading session, marking a -0.64% move from the prior day.
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
by Zacks Equity Research
Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.
Pharma Stock Roundup: FDA Nod to GSK's MMR Jab & SNY's Dupixent Expanded Use
by Kinjel Shah
European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.
The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics
by Zacks Equity Research
Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.
Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More
by Zacks Equity Research
Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.
Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year
by Zacks Equity Research
Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
by Zacks Equity Research
Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.
Regeneron (REGN) Down 1.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag
by Zacks Equity Research
The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
by Zacks Equity Research
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
by Zacks Equity Research
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study
by Zacks Equity Research
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical
by Zacks Equity Research
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog
Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News
by Ekta Bagri
Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.